Warns of Major Challenges Facing Drug Pricing Policy in America
Vas Narasimhan, CEO of Novartis, warns that the drug pricing policy established by President Trump will have negative repercussions for both pharmaceutical companies and patients. The effects of these policies are expected to manifest in the next eighteen months.